nodes	percent_of_prediction	percent_of_DWPC	metapath
Almotriptan—CYP3A4—bone cancer	0.73	1	CbGaD
Almotriptan—HTR1B—dura mater—bone cancer	0.023	0.272	CbGeAlD
Almotriptan—HTR1D—dura mater—bone cancer	0.0223	0.263	CbGeAlD
Almotriptan—HTR1B—trigeminal nerve—bone cancer	0.00989	0.117	CbGeAlD
Almotriptan—HTR1D—trigeminal nerve—bone cancer	0.00957	0.113	CbGeAlD
Almotriptan—HTR1B—cranial nerve—bone cancer	0.00705	0.0833	CbGeAlD
Almotriptan—HTR1D—cranial nerve—bone cancer	0.00682	0.0807	CbGeAlD
Almotriptan—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.00571	0.0765	CbGpPWpGaD
Almotriptan—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00343	0.046	CbGpPWpGaD
Almotriptan—FMO3—SIDS Susceptibility Pathways—FEV—bone cancer	0.00302	0.0404	CbGpPWpGaD
Almotriptan—FMO3—Tamoxifen metabolism—CYP3A4—bone cancer	0.00297	0.0398	CbGpPWpGaD
Almotriptan—FMO3—Metapathway biotransformation—CYP4V2—bone cancer	0.00275	0.0369	CbGpPWpGaD
Almotriptan—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00187	0.0251	CbGpPWpGaD
Almotriptan—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00162	0.0217	CbGpPWpGaD
Almotriptan—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00155	0.0208	CbGpPWpGaD
Almotriptan—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00145	0.0194	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—FEV—bone cancer	0.00144	0.0193	CbGpPWpGaD
Almotriptan—HTR1D—connective tissue—bone cancer	0.00141	0.0166	CbGeAlD
Almotriptan—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00134	0.0179	CbGpPWpGaD
Almotriptan—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00133	0.0178	CbGpPWpGaD
Almotriptan—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00126	0.0169	CbGpPWpGaD
Almotriptan—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00113	0.0151	CbGpPWpGaD
Almotriptan—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00108	0.0145	CbGpPWpGaD
Almotriptan—MAOA—connective tissue—bone cancer	0.00107	0.0127	CbGeAlD
Almotriptan—FMO3—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00104	0.0139	CbGpPWpGaD
Almotriptan—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00101	0.0136	CbGpPWpGaD
Almotriptan—HTR1B—spinal cord—bone cancer	0.000964	0.0114	CbGeAlD
Almotriptan—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.000904	0.0121	CbGpPWpGaD
Almotriptan—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.00087	0.0117	CbGpPWpGaD
Almotriptan—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000869	0.0117	CbGpPWpGaD
Almotriptan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000818	0.011	CbGpPWpGaD
Almotriptan—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000806	0.0108	CbGpPWpGaD
Almotriptan—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000782	0.0105	CbGpPWpGaD
Almotriptan—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000767	0.0103	CbGpPWpGaD
Almotriptan—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000752	0.0101	CbGpPWpGaD
Almotriptan—MAOA—tendon—bone cancer	0.000737	0.00871	CbGeAlD
Almotriptan—MAOA—spinal cord—bone cancer	0.00071	0.0084	CbGeAlD
Almotriptan—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000698	0.00935	CbGpPWpGaD
Almotriptan—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000697	0.00934	CbGpPWpGaD
Almotriptan—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000671	0.00899	CbGpPWpGaD
Almotriptan—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00065	0.00871	CbGpPWpGaD
Almotriptan—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000642	0.0086	CbGpPWpGaD
Almotriptan—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000622	0.00834	CbGpPWpGaD
Almotriptan—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000617	0.00827	CbGpPWpGaD
Almotriptan—Dry eye—Epirubicin—bone cancer	0.000615	0.00555	CcSEcCtD
Almotriptan—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000609	0.00816	CbGpPWpGaD
Almotriptan—Eye disorder—Cisplatin—bone cancer	0.000608	0.00549	CcSEcCtD
Almotriptan—Tinnitus—Cisplatin—bone cancer	0.000607	0.00547	CcSEcCtD
Almotriptan—Cardiac disorder—Cisplatin—bone cancer	0.000604	0.00545	CcSEcCtD
Almotriptan—Salivary hypersecretion—Doxorubicin—bone cancer	0.000598	0.0054	CcSEcCtD
Almotriptan—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000592	0.00793	CbGpPWpGaD
Almotriptan—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000591	0.00793	CbGpPWpGaD
Almotriptan—Colitis—Doxorubicin—bone cancer	0.000591	0.00533	CcSEcCtD
Almotriptan—Immune system disorder—Cisplatin—bone cancer	0.000588	0.0053	CcSEcCtD
Almotriptan—Hypertonia—Epirubicin—bone cancer	0.000583	0.00526	CcSEcCtD
Almotriptan—Neuropathy—Doxorubicin—bone cancer	0.000578	0.00522	CcSEcCtD
Almotriptan—Mental disability—Epirubicin—bone cancer	0.000578	0.00521	CcSEcCtD
Almotriptan—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000572	0.00767	CbGpPWpGaD
Almotriptan—Dry eye—Doxorubicin—bone cancer	0.000569	0.00513	CcSEcCtD
Almotriptan—Erythema—Cisplatin—bone cancer	0.000567	0.00511	CcSEcCtD
Almotriptan—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000566	0.00759	CbGpPWpGaD
Almotriptan—CYP2E1—tendon—bone cancer	0.000553	0.00654	CbGeAlD
Almotriptan—FMO3—Biological oxidations—CYP3A4—bone cancer	0.000552	0.00739	CbGpPWpGaD
Almotriptan—FMO3—Metapathway biotransformation—CYP3A4—bone cancer	0.000544	0.00729	CbGpPWpGaD
Almotriptan—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000544	0.00729	CbGpPWpGaD
Almotriptan—Hypertonia—Doxorubicin—bone cancer	0.00054	0.00487	CcSEcCtD
Almotriptan—Eye pain—Epirubicin—bone cancer	0.000535	0.00483	CcSEcCtD
Almotriptan—Mental disability—Doxorubicin—bone cancer	0.000534	0.00482	CcSEcCtD
Almotriptan—Vision blurred—Cisplatin—bone cancer	0.000534	0.00482	CcSEcCtD
Almotriptan—CYP2E1—spinal cord—bone cancer	0.000533	0.00631	CbGeAlD
Almotriptan—Tremor—Cisplatin—bone cancer	0.000531	0.00479	CcSEcCtD
Almotriptan—Ill-defined disorder—Cisplatin—bone cancer	0.000526	0.00474	CcSEcCtD
Almotriptan—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000523	0.00701	CbGpPWpGaD
Almotriptan—Malaise—Cisplatin—bone cancer	0.000511	0.00461	CcSEcCtD
Almotriptan—MAOA—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000496	0.00665	CbGpPWpGaD
Almotriptan—Eye pain—Doxorubicin—bone cancer	0.000495	0.00447	CcSEcCtD
Almotriptan—Convulsion—Cisplatin—bone cancer	0.000491	0.00443	CcSEcCtD
Almotriptan—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000485	0.0065	CbGpPWpGaD
Almotriptan—Pain in extremity—Epirubicin—bone cancer	0.000483	0.00436	CcSEcCtD
Almotriptan—Diplopia—Epirubicin—bone cancer	0.000483	0.00436	CcSEcCtD
Almotriptan—Myalgia—Cisplatin—bone cancer	0.000482	0.00435	CcSEcCtD
Almotriptan—Anxiety—Cisplatin—bone cancer	0.000481	0.00434	CcSEcCtD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000479	0.00432	CcSEcCtD
Almotriptan—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000479	0.00642	CbGpPWpGaD
Almotriptan—Discomfort—Cisplatin—bone cancer	0.000477	0.0043	CcSEcCtD
Almotriptan—FMO3—Biological oxidations—GSTP1—bone cancer	0.000472	0.00632	CbGpPWpGaD
Almotriptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00047	0.0063	CbGpPWpGaD
Almotriptan—Breast disorder—Methotrexate—bone cancer	0.000467	0.00421	CcSEcCtD
Almotriptan—FMO3—Metapathway biotransformation—GSTP1—bone cancer	0.000465	0.00624	CbGpPWpGaD
Almotriptan—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000464	0.00623	CbGpPWpGaD
Almotriptan—Anaphylactic shock—Cisplatin—bone cancer	0.000462	0.00417	CcSEcCtD
Almotriptan—HTR1D—G alpha (i) signalling events—GRM4—bone cancer	0.000462	0.00619	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—RGS1—bone cancer	0.000462	0.00619	CbGpPWpGaD
Almotriptan—Nervous system disorder—Cisplatin—bone cancer	0.000454	0.00409	CcSEcCtD
Almotriptan—HTR1B—G alpha (i) signalling events—RGS1—bone cancer	0.000452	0.00606	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—GRM4—bone cancer	0.000452	0.00606	CbGpPWpGaD
Almotriptan—Tachycardia—Cisplatin—bone cancer	0.000451	0.00407	CcSEcCtD
Almotriptan—Skin disorder—Cisplatin—bone cancer	0.000449	0.00405	CcSEcCtD
Almotriptan—Diplopia—Doxorubicin—bone cancer	0.000447	0.00403	CcSEcCtD
Almotriptan—Pain in extremity—Doxorubicin—bone cancer	0.000447	0.00403	CcSEcCtD
Almotriptan—Hyperhidrosis—Cisplatin—bone cancer	0.000447	0.00403	CcSEcCtD
Almotriptan—Abdominal pain upper—Epirubicin—bone cancer	0.000441	0.00398	CcSEcCtD
Almotriptan—Breast disorder—Epirubicin—bone cancer	0.000437	0.00394	CcSEcCtD
Almotriptan—Abdominal discomfort—Methotrexate—bone cancer	0.000428	0.00386	CcSEcCtD
Almotriptan—Gastritis—Epirubicin—bone cancer	0.000428	0.00386	CcSEcCtD
Almotriptan—Muscular weakness—Epirubicin—bone cancer	0.000426	0.00384	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000421	0.0038	CcSEcCtD
Almotriptan—Paraesthesia—Cisplatin—bone cancer	0.000415	0.00375	CcSEcCtD
Almotriptan—Dyspnoea—Cisplatin—bone cancer	0.000412	0.00372	CcSEcCtD
Almotriptan—Abdominal pain upper—Doxorubicin—bone cancer	0.000408	0.00368	CcSEcCtD
Almotriptan—Photosensitivity reaction—Methotrexate—bone cancer	0.000407	0.00367	CcSEcCtD
Almotriptan—Angina pectoris—Epirubicin—bone cancer	0.000407	0.00367	CcSEcCtD
Almotriptan—Breast disorder—Doxorubicin—bone cancer	0.000404	0.00364	CcSEcCtD
Almotriptan—Bronchitis—Epirubicin—bone cancer	0.000402	0.00362	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Cisplatin—bone cancer	0.000399	0.0036	CcSEcCtD
Almotriptan—Gastritis—Doxorubicin—bone cancer	0.000396	0.00357	CcSEcCtD
Almotriptan—Pain—Cisplatin—bone cancer	0.000395	0.00357	CcSEcCtD
Almotriptan—Muscular weakness—Doxorubicin—bone cancer	0.000394	0.00356	CcSEcCtD
Almotriptan—Conjunctivitis—Methotrexate—bone cancer	0.000387	0.00349	CcSEcCtD
Almotriptan—Photosensitivity reaction—Epirubicin—bone cancer	0.000381	0.00344	CcSEcCtD
Almotriptan—Feeling abnormal—Cisplatin—bone cancer	0.000381	0.00344	CcSEcCtD
Almotriptan—Hyperglycaemia—Epirubicin—bone cancer	0.000377	0.0034	CcSEcCtD
Almotriptan—Angina pectoris—Doxorubicin—bone cancer	0.000376	0.0034	CcSEcCtD
Almotriptan—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000376	0.00503	CbGpPWpGaD
Almotriptan—Epistaxis—Methotrexate—bone cancer	0.000375	0.00339	CcSEcCtD
Almotriptan—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000374	0.00501	CbGpPWpGaD
Almotriptan—Bronchitis—Doxorubicin—bone cancer	0.000372	0.00335	CcSEcCtD
Almotriptan—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000371	0.00497	CbGpPWpGaD
Almotriptan—Body temperature increased—Cisplatin—bone cancer	0.000366	0.0033	CcSEcCtD
Almotriptan—Neuropathy peripheral—Epirubicin—bone cancer	0.000365	0.00329	CcSEcCtD
Almotriptan—Conjunctivitis—Epirubicin—bone cancer	0.000362	0.00326	CcSEcCtD
Almotriptan—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000356	0.00477	CbGpPWpGaD
Almotriptan—Pharyngitis—Methotrexate—bone cancer	0.000355	0.0032	CcSEcCtD
Almotriptan—Photosensitivity reaction—Doxorubicin—bone cancer	0.000353	0.00318	CcSEcCtD
Almotriptan—Epistaxis—Epirubicin—bone cancer	0.000351	0.00317	CcSEcCtD
Almotriptan—Sinusitis—Epirubicin—bone cancer	0.000349	0.00315	CcSEcCtD
Almotriptan—Hyperglycaemia—Doxorubicin—bone cancer	0.000349	0.00314	CcSEcCtD
Almotriptan—Visual impairment—Methotrexate—bone cancer	0.000344	0.00311	CcSEcCtD
Almotriptan—Hypersensitivity—Cisplatin—bone cancer	0.000341	0.00307	CcSEcCtD
Almotriptan—Neuropathy peripheral—Doxorubicin—bone cancer	0.000338	0.00305	CcSEcCtD
Almotriptan—Rhinitis—Epirubicin—bone cancer	0.000335	0.00302	CcSEcCtD
Almotriptan—Conjunctivitis—Doxorubicin—bone cancer	0.000335	0.00302	CcSEcCtD
Almotriptan—Eye disorder—Methotrexate—bone cancer	0.000334	0.00301	CcSEcCtD
Almotriptan—Tinnitus—Methotrexate—bone cancer	0.000333	0.003	CcSEcCtD
Almotriptan—Hypoaesthesia—Epirubicin—bone cancer	0.000333	0.003	CcSEcCtD
Almotriptan—Asthenia—Cisplatin—bone cancer	0.000332	0.00299	CcSEcCtD
Almotriptan—Pharyngitis—Epirubicin—bone cancer	0.000332	0.00299	CcSEcCtD
Almotriptan—Cardiac disorder—Methotrexate—bone cancer	0.000332	0.00299	CcSEcCtD
Almotriptan—FMO3—Metabolism—NDUFA12—bone cancer	0.000331	0.00443	CbGpPWpGaD
Almotriptan—Epistaxis—Doxorubicin—bone cancer	0.000325	0.00293	CcSEcCtD
Almotriptan—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000325	0.00435	CbGpPWpGaD
Almotriptan—Sinusitis—Doxorubicin—bone cancer	0.000323	0.00292	CcSEcCtD
Almotriptan—Immune system disorder—Methotrexate—bone cancer	0.000323	0.00291	CcSEcCtD
Almotriptan—Visual impairment—Epirubicin—bone cancer	0.000322	0.00291	CcSEcCtD
Almotriptan—Chills—Methotrexate—bone cancer	0.000321	0.00289	CcSEcCtD
Almotriptan—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00032	0.00429	CbGpPWpGaD
Almotriptan—Diarrhoea—Cisplatin—bone cancer	0.000316	0.00285	CcSEcCtD
Almotriptan—Mental disorder—Methotrexate—bone cancer	0.000313	0.00282	CcSEcCtD
Almotriptan—Eye disorder—Epirubicin—bone cancer	0.000312	0.00282	CcSEcCtD
Almotriptan—Tinnitus—Epirubicin—bone cancer	0.000312	0.00281	CcSEcCtD
Almotriptan—Erythema—Methotrexate—bone cancer	0.000311	0.0028	CcSEcCtD
Almotriptan—Cardiac disorder—Epirubicin—bone cancer	0.00031	0.0028	CcSEcCtD
Almotriptan—Rhinitis—Doxorubicin—bone cancer	0.00031	0.0028	CcSEcCtD
Almotriptan—Hypoaesthesia—Doxorubicin—bone cancer	0.000308	0.00278	CcSEcCtD
Almotriptan—Pharyngitis—Doxorubicin—bone cancer	0.000307	0.00277	CcSEcCtD
Almotriptan—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000307	0.00411	CbGpPWpGaD
Almotriptan—Dysgeusia—Methotrexate—bone cancer	0.000305	0.00275	CcSEcCtD
Almotriptan—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000304	0.00408	CbGpPWpGaD
Almotriptan—Immune system disorder—Epirubicin—bone cancer	0.000302	0.00272	CcSEcCtD
Almotriptan—Back pain—Methotrexate—bone cancer	0.000301	0.00271	CcSEcCtD
Almotriptan—Chills—Epirubicin—bone cancer	0.0003	0.00271	CcSEcCtD
Almotriptan—Visual impairment—Doxorubicin—bone cancer	0.000298	0.00269	CcSEcCtD
Almotriptan—Vomiting—Cisplatin—bone cancer	0.000294	0.00265	CcSEcCtD
Almotriptan—Vision blurred—Methotrexate—bone cancer	0.000293	0.00264	CcSEcCtD
Almotriptan—Mental disorder—Epirubicin—bone cancer	0.000293	0.00264	CcSEcCtD
Almotriptan—Rash—Cisplatin—bone cancer	0.000292	0.00263	CcSEcCtD
Almotriptan—Dermatitis—Cisplatin—bone cancer	0.000291	0.00263	CcSEcCtD
Almotriptan—Erythema—Epirubicin—bone cancer	0.000291	0.00262	CcSEcCtD
Almotriptan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00029	0.00388	CbGpPWpGaD
Almotriptan—Eye disorder—Doxorubicin—bone cancer	0.000289	0.00261	CcSEcCtD
Almotriptan—Ill-defined disorder—Methotrexate—bone cancer	0.000289	0.0026	CcSEcCtD
Almotriptan—Tinnitus—Doxorubicin—bone cancer	0.000288	0.0026	CcSEcCtD
Almotriptan—Cardiac disorder—Doxorubicin—bone cancer	0.000287	0.00259	CcSEcCtD
Almotriptan—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000286	0.00383	CbGpPWpGaD
Almotriptan—Tension—Epirubicin—bone cancer	0.000286	0.00258	CcSEcCtD
Almotriptan—Dysgeusia—Epirubicin—bone cancer	0.000285	0.00257	CcSEcCtD
Almotriptan—Nervousness—Epirubicin—bone cancer	0.000283	0.00255	CcSEcCtD
Almotriptan—Back pain—Epirubicin—bone cancer	0.000281	0.00254	CcSEcCtD
Almotriptan—Malaise—Methotrexate—bone cancer	0.00028	0.00253	CcSEcCtD
Almotriptan—HTR1D—GPCR ligand binding—GRM4—bone cancer	0.00028	0.00375	CbGpPWpGaD
Almotriptan—Immune system disorder—Doxorubicin—bone cancer	0.000279	0.00252	CcSEcCtD
Almotriptan—Vertigo—Methotrexate—bone cancer	0.000279	0.00252	CcSEcCtD
Almotriptan—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000279	0.00374	CbGpPWpGaD
Almotriptan—Chills—Doxorubicin—bone cancer	0.000278	0.0025	CcSEcCtD
Almotriptan—Nausea—Cisplatin—bone cancer	0.000275	0.00248	CcSEcCtD
Almotriptan—Vision blurred—Epirubicin—bone cancer	0.000274	0.00247	CcSEcCtD
Almotriptan—FMO3—Metabolism—NT5C3A—bone cancer	0.000274	0.00367	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—GRM4—bone cancer	0.000274	0.00367	CbGpPWpGaD
Almotriptan—Mental disorder—Doxorubicin—bone cancer	0.000271	0.00244	CcSEcCtD
Almotriptan—Ill-defined disorder—Epirubicin—bone cancer	0.00027	0.00244	CcSEcCtD
Almotriptan—Convulsion—Methotrexate—bone cancer	0.000269	0.00243	CcSEcCtD
Almotriptan—Erythema—Doxorubicin—bone cancer	0.000269	0.00243	CcSEcCtD
Almotriptan—Agitation—Epirubicin—bone cancer	0.000267	0.00241	CcSEcCtD
Almotriptan—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000266	0.00357	CbGpPWpGaD
Almotriptan—Arthralgia—Methotrexate—bone cancer	0.000265	0.00239	CcSEcCtD
Almotriptan—Chest pain—Methotrexate—bone cancer	0.000265	0.00239	CcSEcCtD
Almotriptan—Myalgia—Methotrexate—bone cancer	0.000265	0.00239	CcSEcCtD
Almotriptan—Tension—Doxorubicin—bone cancer	0.000264	0.00238	CcSEcCtD
Almotriptan—Dysgeusia—Doxorubicin—bone cancer	0.000264	0.00238	CcSEcCtD
Almotriptan—MAOA—Biological oxidations—CYP3A4—bone cancer	0.000264	0.00353	CbGpPWpGaD
Almotriptan—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000263	0.00353	CbGpPWpGaD
Almotriptan—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000263	0.00352	CbGpPWpGaD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000263	0.00237	CcSEcCtD
Almotriptan—Malaise—Epirubicin—bone cancer	0.000262	0.00237	CcSEcCtD
Almotriptan—Discomfort—Methotrexate—bone cancer	0.000262	0.00236	CcSEcCtD
Almotriptan—Nervousness—Doxorubicin—bone cancer	0.000262	0.00236	CcSEcCtD
Almotriptan—Vertigo—Epirubicin—bone cancer	0.000261	0.00236	CcSEcCtD
Almotriptan—Syncope—Epirubicin—bone cancer	0.000261	0.00235	CcSEcCtD
Almotriptan—Back pain—Doxorubicin—bone cancer	0.00026	0.00235	CcSEcCtD
Almotriptan—Palpitations—Epirubicin—bone cancer	0.000257	0.00232	CcSEcCtD
Almotriptan—Confusional state—Methotrexate—bone cancer	0.000256	0.00231	CcSEcCtD
Almotriptan—Loss of consciousness—Epirubicin—bone cancer	0.000256	0.00231	CcSEcCtD
Almotriptan—Anaphylactic shock—Methotrexate—bone cancer	0.000254	0.00229	CcSEcCtD
Almotriptan—Vision blurred—Doxorubicin—bone cancer	0.000254	0.00229	CcSEcCtD
Almotriptan—Convulsion—Epirubicin—bone cancer	0.000252	0.00227	CcSEcCtD
Almotriptan—Hypertension—Epirubicin—bone cancer	0.000251	0.00227	CcSEcCtD
Almotriptan—Ill-defined disorder—Doxorubicin—bone cancer	0.00025	0.00225	CcSEcCtD
Almotriptan—Nervous system disorder—Methotrexate—bone cancer	0.000249	0.00224	CcSEcCtD
Almotriptan—Chest pain—Epirubicin—bone cancer	0.000248	0.00223	CcSEcCtD
Almotriptan—Myalgia—Epirubicin—bone cancer	0.000248	0.00223	CcSEcCtD
Almotriptan—Arthralgia—Epirubicin—bone cancer	0.000248	0.00223	CcSEcCtD
Almotriptan—Agitation—Doxorubicin—bone cancer	0.000247	0.00223	CcSEcCtD
Almotriptan—Anxiety—Epirubicin—bone cancer	0.000247	0.00223	CcSEcCtD
Almotriptan—Skin disorder—Methotrexate—bone cancer	0.000246	0.00222	CcSEcCtD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000246	0.00222	CcSEcCtD
Almotriptan—Hyperhidrosis—Methotrexate—bone cancer	0.000245	0.00221	CcSEcCtD
Almotriptan—Discomfort—Epirubicin—bone cancer	0.000245	0.00221	CcSEcCtD
Almotriptan—Malaise—Doxorubicin—bone cancer	0.000243	0.00219	CcSEcCtD
Almotriptan—HTR1D—GPCR ligand binding—GRM1—bone cancer	0.000243	0.00325	CbGpPWpGaD
Almotriptan—Dry mouth—Epirubicin—bone cancer	0.000242	0.00219	CcSEcCtD
Almotriptan—Vertigo—Doxorubicin—bone cancer	0.000242	0.00218	CcSEcCtD
Almotriptan—Syncope—Doxorubicin—bone cancer	0.000241	0.00218	CcSEcCtD
Almotriptan—Confusional state—Epirubicin—bone cancer	0.000239	0.00216	CcSEcCtD
Almotriptan—FMO3—SIDS Susceptibility Pathways—JUN—bone cancer	0.000238	0.00319	CbGpPWpGaD
Almotriptan—Palpitations—Doxorubicin—bone cancer	0.000238	0.00215	CcSEcCtD
Almotriptan—Anaphylactic shock—Epirubicin—bone cancer	0.000237	0.00214	CcSEcCtD
Almotriptan—HTR1B—GPCR ligand binding—GRM1—bone cancer	0.000237	0.00318	CbGpPWpGaD
Almotriptan—Loss of consciousness—Doxorubicin—bone cancer	0.000237	0.00213	CcSEcCtD
Almotriptan—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000235	0.00315	CbGpPWpGaD
Almotriptan—Shock—Epirubicin—bone cancer	0.000234	0.00211	CcSEcCtD
Almotriptan—Convulsion—Doxorubicin—bone cancer	0.000233	0.0021	CcSEcCtD
Almotriptan—Nervous system disorder—Epirubicin—bone cancer	0.000233	0.0021	CcSEcCtD
Almotriptan—Hypertension—Doxorubicin—bone cancer	0.000232	0.0021	CcSEcCtD
Almotriptan—Tachycardia—Epirubicin—bone cancer	0.000232	0.00209	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000231	0.00209	CcSEcCtD
Almotriptan—Skin disorder—Epirubicin—bone cancer	0.000231	0.00208	CcSEcCtD
Almotriptan—Hyperhidrosis—Epirubicin—bone cancer	0.00023	0.00207	CcSEcCtD
Almotriptan—Insomnia—Methotrexate—bone cancer	0.00023	0.00207	CcSEcCtD
Almotriptan—Arthralgia—Doxorubicin—bone cancer	0.000229	0.00207	CcSEcCtD
Almotriptan—Chest pain—Doxorubicin—bone cancer	0.000229	0.00207	CcSEcCtD
Almotriptan—Myalgia—Doxorubicin—bone cancer	0.000229	0.00207	CcSEcCtD
Almotriptan—Anxiety—Doxorubicin—bone cancer	0.000228	0.00206	CcSEcCtD
Almotriptan—Paraesthesia—Methotrexate—bone cancer	0.000228	0.00206	CcSEcCtD
Almotriptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000228	0.00205	CcSEcCtD
Almotriptan—Discomfort—Doxorubicin—bone cancer	0.000226	0.00204	CcSEcCtD
Almotriptan—Dyspnoea—Methotrexate—bone cancer	0.000226	0.00204	CcSEcCtD
Almotriptan—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000226	0.00303	CbGpPWpGaD
Almotriptan—Somnolence—Methotrexate—bone cancer	0.000226	0.00204	CcSEcCtD
Almotriptan—MAOA—Biological oxidations—GSTP1—bone cancer	0.000225	0.00302	CbGpPWpGaD
Almotriptan—Dry mouth—Doxorubicin—bone cancer	0.000224	0.00202	CcSEcCtD
Almotriptan—Dyspepsia—Methotrexate—bone cancer	0.000223	0.00202	CcSEcCtD
Almotriptan—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000223	0.00299	CbGpPWpGaD
Almotriptan—Confusional state—Doxorubicin—bone cancer	0.000222	0.002	CcSEcCtD
Almotriptan—Anaphylactic shock—Doxorubicin—bone cancer	0.00022	0.00198	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Methotrexate—bone cancer	0.000219	0.00198	CcSEcCtD
Almotriptan—Fatigue—Methotrexate—bone cancer	0.000219	0.00197	CcSEcCtD
Almotriptan—Pain—Methotrexate—bone cancer	0.000217	0.00196	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000216	0.00195	CcSEcCtD
Almotriptan—Shock—Doxorubicin—bone cancer	0.000216	0.00195	CcSEcCtD
Almotriptan—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000216	0.0029	CbGpPWpGaD
Almotriptan—Nervous system disorder—Doxorubicin—bone cancer	0.000215	0.00194	CcSEcCtD
Almotriptan—Insomnia—Epirubicin—bone cancer	0.000215	0.00194	CcSEcCtD
Almotriptan—Tachycardia—Doxorubicin—bone cancer	0.000214	0.00193	CcSEcCtD
Almotriptan—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000213	0.00286	CbGpPWpGaD
Almotriptan—Skin disorder—Doxorubicin—bone cancer	0.000213	0.00193	CcSEcCtD
Almotriptan—Paraesthesia—Epirubicin—bone cancer	0.000213	0.00192	CcSEcCtD
Almotriptan—Hyperhidrosis—Doxorubicin—bone cancer	0.000212	0.00192	CcSEcCtD
Almotriptan—Dyspnoea—Epirubicin—bone cancer	0.000212	0.00191	CcSEcCtD
Almotriptan—Somnolence—Epirubicin—bone cancer	0.000211	0.0019	CcSEcCtD
Almotriptan—Feeling abnormal—Methotrexate—bone cancer	0.000209	0.00189	CcSEcCtD
Almotriptan—Dyspepsia—Epirubicin—bone cancer	0.000209	0.00189	CcSEcCtD
Almotriptan—Gastrointestinal pain—Methotrexate—bone cancer	0.000208	0.00187	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Epirubicin—bone cancer	0.000205	0.00185	CcSEcCtD
Almotriptan—Fatigue—Epirubicin—bone cancer	0.000205	0.00185	CcSEcCtD
Almotriptan—Pain—Epirubicin—bone cancer	0.000203	0.00183	CcSEcCtD
Almotriptan—Body temperature increased—Methotrexate—bone cancer	0.000201	0.00181	CcSEcCtD
Almotriptan—Abdominal pain—Methotrexate—bone cancer	0.000201	0.00181	CcSEcCtD
Almotriptan—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.0002	0.00181	CcSEcCtD
Almotriptan—Insomnia—Doxorubicin—bone cancer	0.000199	0.00179	CcSEcCtD
Almotriptan—Paraesthesia—Doxorubicin—bone cancer	0.000197	0.00178	CcSEcCtD
Almotriptan—Dyspnoea—Doxorubicin—bone cancer	0.000196	0.00177	CcSEcCtD
Almotriptan—Feeling abnormal—Epirubicin—bone cancer	0.000196	0.00177	CcSEcCtD
Almotriptan—Somnolence—Doxorubicin—bone cancer	0.000195	0.00176	CcSEcCtD
Almotriptan—Gastrointestinal pain—Epirubicin—bone cancer	0.000194	0.00175	CcSEcCtD
Almotriptan—Dyspepsia—Doxorubicin—bone cancer	0.000193	0.00174	CcSEcCtD
Almotriptan—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00019	0.00171	CcSEcCtD
Almotriptan—Fatigue—Doxorubicin—bone cancer	0.000189	0.00171	CcSEcCtD
Almotriptan—Pain—Doxorubicin—bone cancer	0.000188	0.0017	CcSEcCtD
Almotriptan—Abdominal pain—Epirubicin—bone cancer	0.000188	0.00169	CcSEcCtD
Almotriptan—Body temperature increased—Epirubicin—bone cancer	0.000188	0.00169	CcSEcCtD
Almotriptan—Hypersensitivity—Methotrexate—bone cancer	0.000187	0.00169	CcSEcCtD
Almotriptan—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000183	0.00245	CbGpPWpGaD
Almotriptan—Asthenia—Methotrexate—bone cancer	0.000182	0.00164	CcSEcCtD
Almotriptan—Feeling abnormal—Doxorubicin—bone cancer	0.000181	0.00163	CcSEcCtD
Almotriptan—Gastrointestinal pain—Doxorubicin—bone cancer	0.00018	0.00162	CcSEcCtD
Almotriptan—Pruritus—Methotrexate—bone cancer	0.00018	0.00162	CcSEcCtD
Almotriptan—Hypersensitivity—Epirubicin—bone cancer	0.000175	0.00158	CcSEcCtD
Almotriptan—Abdominal pain—Doxorubicin—bone cancer	0.000174	0.00157	CcSEcCtD
Almotriptan—Body temperature increased—Doxorubicin—bone cancer	0.000174	0.00157	CcSEcCtD
Almotriptan—Diarrhoea—Methotrexate—bone cancer	0.000174	0.00157	CcSEcCtD
Almotriptan—HTR1D—GPCR ligand binding—SMO—bone cancer	0.000171	0.00229	CbGpPWpGaD
Almotriptan—Asthenia—Epirubicin—bone cancer	0.00017	0.00154	CcSEcCtD
Almotriptan—Pruritus—Epirubicin—bone cancer	0.000168	0.00152	CcSEcCtD
Almotriptan—Dizziness—Methotrexate—bone cancer	0.000168	0.00151	CcSEcCtD
Almotriptan—HTR1B—GPCR ligand binding—SMO—bone cancer	0.000167	0.00224	CbGpPWpGaD
Almotriptan—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000166	0.00223	CbGpPWpGaD
Almotriptan—Diarrhoea—Epirubicin—bone cancer	0.000162	0.00147	CcSEcCtD
Almotriptan—Hypersensitivity—Doxorubicin—bone cancer	0.000162	0.00146	CcSEcCtD
Almotriptan—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000162	0.00217	CbGpPWpGaD
Almotriptan—Vomiting—Methotrexate—bone cancer	0.000161	0.00146	CcSEcCtD
Almotriptan—Rash—Methotrexate—bone cancer	0.00016	0.00144	CcSEcCtD
Almotriptan—Dermatitis—Methotrexate—bone cancer	0.00016	0.00144	CcSEcCtD
Almotriptan—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000159	0.00214	CbGpPWpGaD
Almotriptan—Headache—Methotrexate—bone cancer	0.000159	0.00143	CcSEcCtD
Almotriptan—HTR1D—GPCR downstream signaling—GRM4—bone cancer	0.000158	0.00212	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—RGS1—bone cancer	0.000158	0.00212	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—NDUFA12—bone cancer	0.000158	0.00212	CbGpPWpGaD
Almotriptan—Asthenia—Doxorubicin—bone cancer	0.000158	0.00142	CcSEcCtD
Almotriptan—Dizziness—Epirubicin—bone cancer	0.000157	0.00142	CcSEcCtD
Almotriptan—Pruritus—Doxorubicin—bone cancer	0.000155	0.0014	CcSEcCtD
Almotriptan—HTR1B—GPCR downstream signaling—RGS1—bone cancer	0.000155	0.00207	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—GRM4—bone cancer	0.000155	0.00207	CbGpPWpGaD
Almotriptan—Vomiting—Epirubicin—bone cancer	0.000151	0.00136	CcSEcCtD
Almotriptan—Nausea—Methotrexate—bone cancer	0.000151	0.00136	CcSEcCtD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000151	0.00202	CbGpPWpGaD
Almotriptan—Diarrhoea—Doxorubicin—bone cancer	0.00015	0.00136	CcSEcCtD
Almotriptan—Rash—Epirubicin—bone cancer	0.00015	0.00135	CcSEcCtD
Almotriptan—Dermatitis—Epirubicin—bone cancer	0.00015	0.00135	CcSEcCtD
Almotriptan—Headache—Epirubicin—bone cancer	0.000149	0.00134	CcSEcCtD
Almotriptan—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000149	0.00199	CbGpPWpGaD
Almotriptan—Dizziness—Doxorubicin—bone cancer	0.000145	0.00131	CcSEcCtD
Almotriptan—HTR1D—Signaling by GPCR—GRM4—bone cancer	0.000144	0.00192	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—RGS1—bone cancer	0.000144	0.00192	CbGpPWpGaD
Almotriptan—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000142	0.0019	CbGpPWpGaD
Almotriptan—Nausea—Epirubicin—bone cancer	0.000141	0.00127	CcSEcCtD
Almotriptan—HTR1B—Signaling by GPCR—GRM4—bone cancer	0.000141	0.00188	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—RGS1—bone cancer	0.000141	0.00188	CbGpPWpGaD
Almotriptan—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.00014	0.00187	CbGpPWpGaD
Almotriptan—Vomiting—Doxorubicin—bone cancer	0.00014	0.00126	CcSEcCtD
Almotriptan—Rash—Doxorubicin—bone cancer	0.000139	0.00125	CcSEcCtD
Almotriptan—Dermatitis—Doxorubicin—bone cancer	0.000138	0.00125	CcSEcCtD
Almotriptan—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000138	0.00185	CbGpPWpGaD
Almotriptan—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000138	0.00185	CbGpPWpGaD
Almotriptan—Headache—Doxorubicin—bone cancer	0.000138	0.00124	CcSEcCtD
Almotriptan—HTR1D—GPCR downstream signaling—GRM1—bone cancer	0.000137	0.00184	CbGpPWpGaD
Almotriptan—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000136	0.00183	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—GRM1—bone cancer	0.000134	0.0018	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—NT5C3A—bone cancer	0.000131	0.00175	CbGpPWpGaD
Almotriptan—Nausea—Doxorubicin—bone cancer	0.000131	0.00118	CcSEcCtD
Almotriptan—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000128	0.00172	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—BRAF—bone cancer	0.000128	0.00172	CbGpPWpGaD
Almotriptan—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000125	0.00167	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—GRM1—bone cancer	0.000124	0.00167	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000124	0.00166	CbGpPWpGaD
Almotriptan—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000123	0.00165	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—GRM1—bone cancer	0.000122	0.00163	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—ENO2—bone cancer	0.00012	0.00161	CbGpPWpGaD
Almotriptan—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.00012	0.0016	CbGpPWpGaD
Almotriptan—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.000118	0.00158	CbGpPWpGaD
Almotriptan—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000116	0.00155	CbGpPWpGaD
Almotriptan—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000115	0.00154	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—JUN—bone cancer	0.000114	0.00153	CbGpPWpGaD
Almotriptan—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000113	0.00152	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000112	0.0015	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—DHFR—bone cancer	0.000111	0.00149	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—MDM2—bone cancer	0.000107	0.00144	CbGpPWpGaD
Almotriptan—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000107	0.00143	CbGpPWpGaD
Almotriptan—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000105	0.00141	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—GNA11—bone cancer	0.000104	0.00139	CbGpPWpGaD
Almotriptan—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	9.9e-05	0.00133	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—BRAF—bone cancer	9.82e-05	0.00132	CbGpPWpGaD
Almotriptan—CYP2D6—Biological oxidations—GSTP1—bone cancer	9.81e-05	0.00132	CbGpPWpGaD
Almotriptan—CYP1A2—Biological oxidations—CYP3A4—bone cancer	9.72e-05	0.0013	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—NDUFA12—bone cancer	9.69e-05	0.0013	CbGpPWpGaD
Almotriptan—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	9.68e-05	0.0013	CbGpPWpGaD
Almotriptan—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	9.59e-05	0.00129	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—CYP3A4—bone cancer	9.43e-05	0.00126	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—GNA11—bone cancer	8.83e-05	0.00118	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	8.77e-05	0.00118	CbGpPWpGaD
Almotriptan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	8.77e-05	0.00118	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—SMO—bone cancer	8.77e-05	0.00118	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—GNA11—bone cancer	8.65e-05	0.00116	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—SMO—bone cancer	8.59e-05	0.00115	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—GRM4—bone cancer	8.48e-05	0.00114	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—RGS1—bone cancer	8.48e-05	0.00114	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—NDUFA12—bone cancer	8.38e-05	0.00112	CbGpPWpGaD
Almotriptan—CYP1A2—Biological oxidations—GSTP1—bone cancer	8.31e-05	0.00111	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—GRM4—bone cancer	8.3e-05	0.00111	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—RGS1—bone cancer	8.3e-05	0.00111	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—MDM2—bone cancer	8.23e-05	0.0011	CbGpPWpGaD
Almotriptan—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	8.2e-05	0.0011	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—GSTP1—bone cancer	8.07e-05	0.00108	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—NT5C3A—bone cancer	8.03e-05	0.00108	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—GNA11—bone cancer	8.02e-05	0.00107	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—IL3—bone cancer	8.01e-05	0.00107	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—GNA11—bone cancer	7.85e-05	0.00105	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—IL3—bone cancer	7.84e-05	0.00105	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—NDUFA12—bone cancer	7.48e-05	0.001	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—GRM1—bone cancer	7.35e-05	0.000985	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—IL3—bone cancer	7.27e-05	0.000975	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—GRM1—bone cancer	7.2e-05	0.000965	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—IL3—bone cancer	7.12e-05	0.000954	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—NT5C3A—bone cancer	6.94e-05	0.00093	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—NDUFA12—bone cancer	6.88e-05	0.000922	CbGpPWpGaD
Almotriptan—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.42e-05	0.00086	CbGpPWpGaD
Almotriptan—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.33e-05	0.000848	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—NT5C3A—bone cancer	6.2e-05	0.000831	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—NDUFA12—bone cancer	5.83e-05	0.000781	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—ENO2—bone cancer	5.73e-05	0.000769	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—NT5C3A—bone cancer	5.7e-05	0.000764	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—DHFR—bone cancer	5.32e-05	0.000713	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—SMO—bone cancer	5.18e-05	0.000694	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—SMO—bone cancer	5.07e-05	0.00068	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—GNA11—bone cancer	4.97e-05	0.000666	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—NT5C3A—bone cancer	4.83e-05	0.000647	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—GNA11—bone cancer	4.74e-05	0.000635	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—GNA11—bone cancer	4.64e-05	0.000622	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—CYP3A4—bone cancer	4.51e-05	0.000604	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—NDUFA12—bone cancer	4.5e-05	0.000603	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—ATF1—bone cancer	4.4e-05	0.00059	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—ATF1—bone cancer	4.31e-05	0.000578	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—IL3—bone cancer	4.3e-05	0.000576	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—IL3—bone cancer	4.21e-05	0.000564	CbGpPWpGaD
Almotriptan—FMO3—Metabolism—PTGS2—bone cancer	4.18e-05	0.00056	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—GSTP1—bone cancer	3.86e-05	0.000517	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—NT5C3A—bone cancer	3.73e-05	0.000499	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—TGFBR2—bone cancer	3.67e-05	0.000492	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—TGFBR2—bone cancer	3.6e-05	0.000482	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—ENO2—bone cancer	3.52e-05	0.000472	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—IGF1R—bone cancer	3.46e-05	0.000463	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—IGF1R—bone cancer	3.38e-05	0.000454	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—DHFR—bone cancer	3.26e-05	0.000437	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—GNA11—bone cancer	3.05e-05	0.000409	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—ENO2—bone cancer	3.04e-05	0.000408	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—DHFR—bone cancer	2.82e-05	0.000378	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—CYP3A4—bone cancer	2.77e-05	0.000371	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—ENO2—bone cancer	2.71e-05	0.000364	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—GNA11—bone cancer	2.64e-05	0.000353	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—DHFR—bone cancer	2.52e-05	0.000337	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—KIT—bone cancer	2.51e-05	0.000336	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—ENO2—bone cancer	2.5e-05	0.000335	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—KIT—bone cancer	2.45e-05	0.000329	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—CYP3A4—bone cancer	2.39e-05	0.00032	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.38e-05	0.000319	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—GSTP1—bone cancer	2.37e-05	0.000317	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—BRAF—bone cancer	2.36e-05	0.000316	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—GNA11—bone cancer	2.35e-05	0.000315	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—DHFR—bone cancer	2.32e-05	0.00031	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—BRAF—bone cancer	2.31e-05	0.000309	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—EGFR—bone cancer	2.28e-05	0.000306	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—EGFR—bone cancer	2.24e-05	0.0003	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—GNA11—bone cancer	2.16e-05	0.00029	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—CYP3A4—bone cancer	2.13e-05	0.000286	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.12e-05	0.000285	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—ENO2—bone cancer	2.11e-05	0.000283	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—GSTP1—bone cancer	2.04e-05	0.000274	CbGpPWpGaD
Almotriptan—MAOA—Metabolism—PTGS2—bone cancer	2e-05	0.000268	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—MDM2—bone cancer	1.97e-05	0.000265	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—CYP3A4—bone cancer	1.96e-05	0.000263	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—DHFR—bone cancer	1.96e-05	0.000263	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—MDM2—bone cancer	1.93e-05	0.000259	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—GNA11—bone cancer	1.83e-05	0.000246	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—GSTP1—bone cancer	1.82e-05	0.000245	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—JUN—bone cancer	1.72e-05	0.00023	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—JUN—bone cancer	1.68e-05	0.000225	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—GSTP1—bone cancer	1.68e-05	0.000225	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—MMP9—bone cancer	1.67e-05	0.000224	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—CYP3A4—bone cancer	1.66e-05	0.000223	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.65e-05	0.000222	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—MMP9—bone cancer	1.63e-05	0.000219	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—ENO2—bone cancer	1.63e-05	0.000219	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—DHFR—bone cancer	1.51e-05	0.000203	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—GSTP1—bone cancer	1.42e-05	0.000191	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—GNA11—bone cancer	1.42e-05	0.00019	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—EGFR—bone cancer	1.35e-05	0.000181	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—EGFR—bone cancer	1.32e-05	0.000177	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—PTGS2—bone cancer	1.23e-05	0.000164	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—TP53—bone cancer	1.13e-05	0.000152	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—TP53—bone cancer	1.11e-05	0.000149	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—GSTP1—bone cancer	1.1e-05	0.000147	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—PTGS2—bone cancer	1.06e-05	0.000142	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—PTGS2—bone cancer	9.45e-06	0.000127	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—PTGS2—bone cancer	8.7e-06	0.000117	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—PTGS2—bone cancer	7.37e-06	9.87e-05	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—PTGS2—bone cancer	5.68e-06	7.62e-05	CbGpPWpGaD
